Basic Information
| LncRNA/CircRNA Name | LINC00473 |
| Synonyms | LINC00473, C6orf176, bA142J11.1 |
| Region | GRCh38_6:165908802-165988048 |
| Ensemble | ENSG00000223414 |
| Refseq | NR_026860 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | wilms tumor |
| ICD-0-3 | C64.9 |
| Methods | qRT- PCR, Western blot, Luciferase reporter assay |
| Sample | Wilms tumour tissues, Wilms tumour cell line (SK-NEP-1) |
| Expression Pattern | up-regulated |
| Function Description | the expression of LINC00473 was elevated in tumour tissues than that in relative normal tissues. Higher LINC00473 levels correlated to higher stage and unfavourable histology Wilms tumour. Mechanistically, knockdown of LINC00473 inhibited cell vitality and induced Bcl-2-dependent apoptosis and G1/S arrest via CDK2 and cyclin D1.Moreover,LINC00473 harboured binding sites for miR-195 and limited miR-195 availability in a dose-dependent manner.Forced expression of miR-195 impaired tumour survival and metastasis, which, however,could be restored by LINC00473. Furthermore, IKKa was the downstream of LINC00473/miR-195 signals and could be directly targeted by miR-195 to participate LINC00473-induced tumour progression. |
| Pubmed ID | 29159834 |
| Year | 2017 |
| Title | LINC00473 antagonizes the tumour suppressor miR-195 to mediate the pathogenesis of Wilms tumour via IKKa. |
External Links
| Links for LINC00473 | GenBank HGNC NONCODE |
| Links for wilms tumor | OMIM COSMIC |